Share Name Share Symbol Market Type Share ISIN Share Description
Tt Electronics Plc LSE:TTG London Ordinary Share GB0008711763 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -0.19% 256.00 1,418,184 16:35:08
Bid Price Offer Price High Price Low Price Open Price
256.00 257.50 258.50 256.50 258.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 431.80 2.90 0.80 320.0 451
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:08 UT 23,320 256.00 GBX

Tt Electronics (TTG) Latest News

More Tt Electronics News
Tt Electronics Investors    Tt Electronics Takeover Rumours

Tt Electronics (TTG) Discussions and Chat

Tt Electronics Forums and Chat

Date Time Title Posts
07/6/202120:43T.T.Electronics charts and news20053,171
15/11/200812:52If TT cuts divi, shares will collapse to 40p9
10/12/200720:42TT Electrincs - borrowings linked to Libor?1
20/4/200616:49TT Electronics -Falls on concerns about trading136

Add a New Thread

Tt Electronics (TTG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-15 15:35:08256.0023,32059,699.20UT
2021-06-15 15:29:55257.50241620.58AT
2021-06-15 15:29:47256.00171437.76O
2021-06-15 15:29:42256.006601,689.60O
2021-06-15 15:29:32257.00250,000642,500.00O
View all Tt Electronics trades in real-time

Tt Electronics (TTG) Top Chat Posts

Tt Electronics Daily Update: Tt Electronics Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker TTG. The last closing price for Tt Electronics was 256.50p.
Tt Electronics Plc has a 4 week average price of 242p and a 12 week average price of 210p.
The 1 year high share price is 282p while the 1 year low share price is currently 159p.
There are currently 176,217,979 shares in issue and the average daily traded volume is 1,240,001 shares. The market capitalisation of Tt Electronics Plc is £451,118,026.24.
earwacks: At the end of the day Ari, it doesn't make any difference what people say. I was really surprised when PS on Stockopeia felt he got stung buying into the spike when Sky broke the story on Virolens in September. Really an experienced investor like him should know better. Buy on rumour sell on news. He spikes shares everyday with his stock reporting. Some of his analysis is excellent and pretty open about not understanding some sectors. They must also be aware that although they are not recommending shares obviously they have a big enough following to effect share price movement to some degree particularly with small companies when they write an enthusiastic report and similarly when they dismiss a company sometimes unjustly. I do occasionally feel I can't let posts go unanswered, when they clearly have the wrong end of the stick or simply too lazy to research themselves just spouting media tosh. Also I find it quite disrespectful to the companies and other genuine investors. I can't remember the inventors name of Iabra, but here is a guy already using AI in other products who had the nowse to come up with this idea, and within three months have the first prototype in partnership wih TTG tested in the field. Genuinely offering a solution in a serious crisis. What do the media do? savage them with their own ignorance stupidity. Dyson was asked by the government if he could help out with the manufacture of ventilators.He agreed to do this on a non profit basis in return that his workers should not have to pay uk tax. Media savage him. AZn no profit making vaccine. The EU want to sue for not fulfilling contract on a vaccine they have clearly stated they won't use. Probably they feel they could have profited from this by selling them on. What is a matter with all these loonies?
earwacks: The MHRA does not issue approvals for COVID-19 tests in the way it does for vaccines, having determined they are effective, but registers medical devices with a certification mark if they meet legal criteria, are safe and are made to the standard specified by the manufacturer for the stated purpose. This is not medicine its a testing device. Histate said trials had indicated the test had 98.1% sensitivity, meaning it returns few false negatives, and 99.7% specificity, meaning few false positives.This is in fact a better result than the one back in September discredited by afore mentioned idiot journalist. "Britain gives the go ahead for Virolens 20 second test.' Those are media headlines not the company headlines. MHRA registration totally legitimises the sale of Virolens in the UK. They seeking similar approval in other countries. They have clearly stated that sales entirely depend on confirmation of interest turning into orders. They satisfactorily completed testing at the Brewery, an events company desperate to reopen within a safe environment in London, like thousands of other businesses and entertainment sports venues around the world. I believe they have now moved on to a London Airport to see how it could operate and help speed up the process of passengers through checks outs. I don't know what on earth you mean when you say 'the purpose for the placing is irrelevant.' One of the most ridiculous statements I have read on any BB.It was quite clearly stated for the reason behind the placing. TTG in no way ramped the product that was entirely down to an Iabra, a statement from the boss at Heathrow, and and over eager journalism hungry for a story. To suggest they suddenly decided to buy an American company on the back of a media story about Virolens is frankly stupid beyond belief. They may have quite sensibly taken advantage of the opportunity that presented itself. Thats what a good business does. To suggest they manufactured a situation like that is quite ludicrous. Virolens is a great British invention that has more potential than any other product on the market to rapidly detect any pathogens being carried by humans or animals after further research. TTG are another very capable British company and I have absolutely no doubt about the integrity of either of them. Finally the boss of Iabra actually apologised for the medias misinterpretation of what he actually said or meant. I don't know if you have ever been interviewed by the media , but I am well aware of media trying to put words into your mouth rather than reporting what you actually say. Its no wonder they are being very much more careful about statements to the press, which is a good thing. In fact the Iabra boss won't speak to media at all now, which is hardly surprising having been ambushed twice at airports. We are great inventors and all the media wants to do is build people up to shoot them down to sell their papers, which is why fewer and fewer people buy their lies. If you don't like these companies thats fine, don't invest. If you are not invested then take your malicious gossip and annoy some other bb please.
sphere25: Big chunks going through at 230p: 2.6m 1m 800k 861k 16:37 UPDATE: Price has held up well on those sells so clearly buyers happy to pick up slugs there. Map it out. Looks like 230p vs 233p. Will keep a watch tomorrow. All imo DYOR
wjccghcc: Regarding MRHA registration, it’s the same requirement as for any of the Lateral Flow Tests that are being used (Excalibur, Innova etc.). They all quote the sensitivity / specificity figures from 400 clinical samples (150 positive / 250 negative) with different viral loads as required by the MHRA. We saw with Innova that the LFT results in real life situations are a lot worse than their registration details. iAbra were running a live trial in February in The City looking for 400 people and then checking them with PCR tests. I’d be surprised if they went ahead with registration if that hadn’t given at least acceptable results, particularly after the media backlash in September. I see there is an instant test centre already set up in the City where they did the trial and watching the video shows it to be a much quicker/simpler/less painful process than LFT/PCR tests. They're charging £50 for an individual test but I suspect a corporate bulk buyer could get them for less than half that. The news has added £45mm to the TTG market cap which is negligible compared to the LFT/PCR providers (AVCT have >450mm, ODX>125mm rises since their LFT news). If it doesn't take off, the downside is 25p but if they do get 100mm orders a year, the upside is at least 4 times that - a good tradeoff IMHO.
earwacks: Hi Glavey. The last placing was to purchase earnings enhancing US electronics and design manufacturer Torotel, nothing to do with virolens. Schroder bought 5% of TTG last week having sold back in September. I think the results of the recent tests of Virolens would absolutely be price sensitive information as will forthcoming orders when received. What they absolutely do not want is misrepresentation by the media again, so they have sensibly been more cautious on fuelling the sensationalist interpretations of the press. Naturally a lot depends on the sales of these machines which have brought a great deal of media attention and interest declared by many sectors of commerce eager to to open up business in a safer environment.
earwacks: Aringading. Some interesting points. Firstly Histate, which is distributing the test, said it would launch with immediate effect following the approval in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), and was hoping for a further rollout in coming months. Histate said trials had indicated the test had 98.1% sensitivity, meaning it returns few false negatives, and 99.7% specificity, meaning few false positives. So I don't think they are any less accurate than the best out there. Secondly its not up to the government to buy them ( they put up 5 million to develop this), possibly local councils could be interested. In the main their customers would be sports and entertainment events, travel, workplace and hospitality. They reckon each machine can do 'hundreds of tests a day so a sports event would probably need about 100 machines. TG have facilities to manufacture these here and in the states and probably other countries too. If the orders become substantial which is quite conceivable TTG will need to scale up production which I would hope they are well prepare for. As regards buying for future pandemics that relies on efforts to redesign virolens to detect other virus and bacterial infections. Work currently in progress
sphere25: Price currently 237p and keeps knocking its head against 240p - clearly sellers in size there at the moment. The first time this news was brought out, the market scrambled all over it with volume approaching 8 million. There was a placing shortly after which did raise a few eyebrows! Clearly the interest isn't there this morning with only 517k shares exchanging hands so far. One to keep an eye on to see if any bigger buyers come in and back what looks like rather uncertain upside potential with Virolens(R). All imo DYOR
earwacks: The problem was more to do with the boss of I-Abra comments about the potential of Virolens.It was him who said the share price of TTG was chicken feed compared to what it would be when orders came in for his invention. TTG are the manufacturers. I-Abra and agents who have bought worldwide distribution rights are responsible for selling the product and authentication. TTG are not out of depth at all the have world wide manufacturing facilities. As have said the government paid initial production costs so far. Sound pretty shrewd to me
peddlers: The price is sitting very close to that trend line. Analyst targets above 240 on TTG. One for the Christmas rush perhaps
imastu pidgitaswell: Some desperate director buys.... Yesterday's were just part of the placement. I'm not close to this, I have been into (not currently in) VLX, so am aware of them and the sector. But honestly, that episode with the CV19 machine, share price soaring and then launching the placement (quickly, but not quickly enough before the truth came out) will count against them for a long time to come.
Tt Electronics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Tt Electro..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210616 02:03:05